Rx Safety: FDA Needs Deadline - Not Funding - To Improve Process, GAO Says
Executive Summary
GAO is not buying an FDA assertion that the delay in giving the Office of Surveillance and Epidemiology more responsibility for post-market drug safety decisions is a funding issue
You may also be interested in...
Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes
The Pharmacovigilance Review Subcommittee of FDA's Science Board reports a lack of clarity within CDER over just what purpose the drug safety program is supposed to serve.
CDER “Equal Voice” Policy Does Not Mean Equal Weight In Decision-Making
The Center for Drug Evaluation and Research’s new internal guidelines implementing the “Equal Voice” initiative suggest each scientific discipline’s perspective will be given equal time, but not equal weight.
CDER “Equal Voice” Policy Does Not Mean Equal Weight In Decision-Making
The Center for Drug Evaluation and Research’s new internal guidelines implementing the “Equal Voice” initiative suggest each scientific discipline’s perspective will be given equal time, but not equal weight.